A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Recruiting now · Phase 1

Conditions studied: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)

In brief

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors

Key facts

Study ID

NCT07085091

Run by

ALX Oncology Inc.

People needed

170

Starts

2025-08-18

Expected to finish

2027-12-01

Last updated by the study team

2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC; locally advanced or recurrent disease must not be amenable to resection with curative intent
• Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced/metastatic setting and for whom no approved or standard therapy is available.
• Dose Exploration and Dose Expansion: The following tumor-specific criteria also apply. These cohorts will include all or a subset of these tumors.
• HNSCC - Received no more than 3 prior lines of therapy in the advanced or metastatic setting
• NSCLC - For participants with a targetable molecular alteration: received appropriate standard targeted therapy and no more than 2 prior lines of systemic chemotherapy in the advanced/metastatic setting. For participants without a targetable molecular alteration: received platinum-based chemotherapy and CPI (in combination or separately), and have received no more than 2 prior lines of systemic chemotherapy in the advanced/metastatic setting
• ESCC - Received no more than 3 prior lines of therapy in the advanced/metastatic setting
• CRC - For participants with a targetable molecular alteration (including dMMR or MSI-H): Received appropriate standard therapy for the alteration, at least 2 prior lines of systemic chemotherapy, and no more than 4 prior lines of therapy in the advanced/metastatic setting. For participants without a targetable molecule alteration: Received at least 2 prior lines of systemic chemotherapy (including an oxaliplatin-based chemotherapy), vascular endothelial growth factor (VEGF)-based therapy, and no more than 4 prior lines of therapy in the advanced/metastatic setting.
• Adequate Bone Marrow Function
• Adequate Renal \& Liver Function
• Adequate Performance Status

You may not qualify if…

• Participants with disease suitable for local therapy with curative intent.
• Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator
• Prior treatment with any ADCs that have an active TOP1 inhibitor-based component

Where it is running

• ALX Center 7 — Tampa, Florida, United States (enrolling)
• ALX Center 8 — Farmington Hills, Michigan, United States (enrolling)
• ALX Center 3 — Grand Rapids, Michigan, United States (enrolling)
• ALX Center 6 — Portland, Oregon, United States (enrolling)
• ALX Center 5 — Houston, Texas, United States (enrolling)
• ALX Center 4 — West Valley City, Utah, United States (enrolling)
• ALX Center 2 — Fairfax, Virginia, United States (enrolling)
• ALX Center 1 — Spokane, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.